Signal Detection And Regulatory Expectations: 2-Day Online Training Course (September 30, 2026 And Oct 1, 2026) With 12 CPD Hours

(MENAFN- GlobeNewsWire - Nasdaq) A detailed, practical overview of all key aspects of safety reviews and signal detection within a company

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Signal Detection and Regulatory Expectations (September 30, 2026 and Oct 1, 2026)" training has been added to ResearchAndMarkets's offering.

Increasingly, the most common critical findings in regulatory inspections relate to signal detection and signal management. As regulatory expectations continue to rise, the ability to identify potential safety signals and risks in patients has never been more important. Protecting patients through robust, structured, and compliant methodologies now requires companies to ensure their teams are highly trained, confident, and competent in these essential activities.

This comprehensive course delivers a detailed, practical overview of all key aspects of safety reviews and signal detection within a company. It covers signal evaluation for both innovator and generic products, in line with the updated Module IX (and addendum) signal management requirements, including the critical links to Risk Management Plans (RMPs) / Risk Evaluation and Mitigation Strategies (REMS). The course also addresses benefit-risk determinations and quantitative signal assessments, providing participants with the knowledge needed to meet regulatory expectations with confidence.

To ensure practical understanding and real-world application, examples and interactive exercises are included throughout the course, enabling delegates to strengthen their skills and apply learning directly to their day-to-day roles.

CPD Hours: 12
Who should attend?

This course is ideal for professionals working in:

• Drug Safety / Pharmacovigilance teams
• EU QP PV/Heads of Pharmacovigilance
• RMP Personnel
• Periodic Report Writers
• Regulatory affairs staff responsible for product labelling updates
• Personnel involved in the preparation of CCSI / DCSI documents

It is designed for anyone who needs practical knowledge of signal detection, safety reviews, and risk management processes.

Key Topics Covered:

• Day 1
  • An introduction to safety signals
  • Causality and signal detection
  • The safety review meeting and process
  • Safety assessments life cycle
  • The regulatory requirements for signal detection - Module IX
  • The signal review cycle
• Day 2
  • Qualitative signal detections
  • Signals and their discussion
  • Safety communication
  • Quantitative signal analysis
  • EVDAS and the EU
  • Risk-benefit analysis

Speaker

Graeme Ladds, Director of PharSafer, has over 30 years' experience in the pharmaceutical industry. He began his career in 1989 at Ashbourne Pharmaceuticals as Head of Drug Safety & Medical Information, before going on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals.

He later founded his consultancy and specialist CRO, PharSafer Associates Ltd, where he has supported companies in establishing pharmacovigilance systems, conducting audits across Europe and the USA, developing SOPs, acting as a QP, and supporting regulatory inspections.

Since 1994, Graeme has also been involved in the monitoring of medical devices, including drug-device combinations, structural devices and electrical medical devices. His experience spans clinical trials and global device vigilance, alongside pharmacovigilance activities across both clinical development and post-marketing phases.

For more information about this training visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11052026004107003653ID1111095634